SCINTIX® biology-guided radiotherapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our X1 platform uses to manage motion and treat solid tumors of any stage disease.
Learn About Emissions
Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.
Learn About Targeting
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Discover the Potential
Treating cancer isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
Learn About Treatment
By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.
Discover SCINTIX therapy.
See how SCINTIX therapy can play a role
in your cancer program.
Unprecedented treatment combines SCINTIX therapy to track tumor motion for precise radiation delivery with stereotactic body radiotherapy HAYWARD, Calif., Sep 5, 2024 – RefleXion Medical, Inc., an external-beam theranostic oncology company, today announced that Smilow Cancer Hospital, part of Yale New Haven Health, Connecticut’s largest health care system, has successfully delivered the world’s first radiotherapy […]
The ribbon cutting at Smilow Cancer Hospital on January 4, 2024, marked a significant milestone in that it has become the first hospital in Connecticut to offer RefleXion Medical’s breakthrough SCINTIX® biology-guided radiotherapy (BgRT). Approximately 430,000 people in the United States are diagnosed annually with tumors originating within or spreading to the lungs or bones. […]
Let us tell you more.
Contact UsStay up to date.
Sign Up